– USA, CA – Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Smith to its Board of Directors as CEO, replacing co-founder and founding CEO, Dr. Pamela Conley who will serve as CSO.
“We are excited by the dynamic leadership, vision, and experience Julie brings to the company and look forward to working closely with her to advance Nuvig’s therapies to patients,” said Dr. Ken Harrison, Board member of Nuvig Therapeutics and Partner at Novo Ventures.
About Julie Anne Smith
Julie Smith has over 20 years of experience in the life science industry, focusing on leading private and public biotech companies through developing and commercializing therapeutics for orphan diseases.
“I’m delighted to join Nuvig at this pivotal time as the team has received strong investor support and rapidly advanced its novel technology to the IND-enabling stage,” said Julie Smith. “I look forward to working with Pam and the team to propel our development candidates into the clinic with the goal of providing new therapeutic options for autoimmune diseases without broad immunosuppression.”
Prior to Nuvig, Ms. Smith served as President and CEO of ESCAPE Bio, a biotech company developing precisely targeted therapies for genetic forms of neurodegeneration. She previously served as President and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections before its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals. Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb. Ms. Smith serves as a director on the Boards of Exelixis (Nasdaq: EXEL) and Stoke Therapeutics (Nasdaq: STOK).
Ms. Smith obtained her B.S. in biology from Cornell University.
About Nuvig Therapeutics
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
For more information: https://www.nuvigtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.